Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company that is focused on the development of prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The company is headquartered in Boulder, Colorado and was founded in 2009. It was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.

Fresh Tracks Therapeutics, Inc. has a portfolio of investigational drug candidates for the treatment of various autoimmune, inflammatory, and other debilitating diseases. The company’s lead product candidate, sofpironium bromide, has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis. In addition, the company is developing BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

The company has several license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Fresh Tracks Therapeutics, Inc. is actively engaged in the research and development of novel therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases.

The company is focused on bringing innovative treatments to patients with unmet medical needs. It is committed to providing safe and effective treatments to patients and their families. The company has an experienced management team and a highly experienced Board of Directors, with extensive experience in the biopharmaceutical industry. The company is also committed to working with regulatory authorities to ensure that its products meet the highest standards of safety and efficacy.